Drug Trial Radar · NCT06981078
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
666
Planned (sponsor's estimate)
Start
Jul 2, 2025
Primary completion
Oct 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Upstream Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- May 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
VerekitugDrug
Verekitug (UPB-101) formulated solution
PlaceboOther
Matching Placebo to Verekitug (UPB-101)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of moderate or severe COPD exacerbation eventsTime frame: From Day 1 (Baseline) up to Week 108
Locations
242 sites in 23 countries. Site status is shown where the registry gives one.
Kern Research Inc.
Bakersfield, California
PulmoCrit Associates
Encino, California
Torrance Clinical Research Institute
Lomita, California
Dream Team Clinical Research
Pomona, California
Apex Clinical Research
San Diego, California
Allianz Research Institute
Westminster, California
D&H Doral Research Center, LLC
Doral, Florida
Qway Research, LLC
Hialeah, Florida
Finlay Medical Research
Miami, Florida
MplusM - ITB Research
Miami, Florida
Florida Institute for Clinical Research,LLC
Orlando, Florida
Velocity Clinical Research-Savannah - Internal Medicine
Savannah, Georgia
Christie Clinic, LLC
Champaign, Illinois
Velocity Clinical Research-Rockville
Rockville, Maryland
Chesapeake Clinical Research, Inc
White Marsh, Maryland
HealthPartners
Saint Paul, Minnesota
American Health Research, Inc.
Charlotte, North Carolina
Velocity Clinical Research, Anderson
Anderson, South Carolina
SleepMed Inc.
Columbia, South Carolina
Velocity Clinical Research, Gaffney
Greenville, South Carolina
Velocity Clinical Research, Spartanburg - Pulmonology
Spartanburg, South Carolina
Velocity Clinical Research- Union
Union, South Carolina
El Paso Pulmonary Association
El Paso, Texas
Victorium Clinical Research
Houston, Texas
Synergy Groups Medical LLC
Houston, Texas
Synergy Groups Medical LLC
Houston, Texas
Metroplex Pulmonary and Sleep Center
McKinney, Texas
Synergy Groups Medical LLC
Missouri City, Texas
Velocity Clinical Research - Suffolk
Suffolk, Virginia
CARE - Centro de Alergia y Enfermedades Respiratorias
Buenos Aires, Buenos Aires, Argentina
Consultorios Médicos Dr. Doreski
Buenos Aires, Buenos Aires, Argentina
Centro de Medicina Respiratoria
Concepción del Uruguay, Entre Ríos Province, Argentina
Fundacion Scherbovsky
Mendoza, Mendoza Province, Argentina
Fundacion Estudios Clinicos (FECLIN)
Rosario, Santa Fe Province, Argentina
Instituto Médico Fundación Grupo Colaborativo Rosario Invest
Rosario, Santa Fe Province, Argentina
Medical Center Pulmo-2018 EOOD
Haskovo, Haskovo, Bulgaria
Medical Center Medconsult Pleven, Lovech branch
Lovech, Lovech, Bulgaria
MEDICAL CENTER HERA EOOD; Office of Pulmonology and Phtisiatrics
Montana, Montana, Bulgaria
SHLTTRPD "Sveta Petka Balgarska" EOOD
Velingrad, Pazardzhik, Bulgaria
Specialized Hospital For Active Treatment Of Pulmonary Diseases Sv.Panteleymon EOOD
Dupnitsa, Pernik, Bulgaria
Showing 40 of 242 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.